COVID-19, Rheumatic Diseases, Vaccination; Infection
Conditions
Brief summary
Many patients develop autoimmune diseases after covid-19 vaccination, whether related to the vaccination or not, is still under study. This study will describe potential flare of ARD after COVID-19 vaccination, whether it leads to activity or new MSK manifestations development.
Detailed description
-In this study: patients with known diagnosed rheumatic diseases who are vaccinated (one or full doses) of any type of COVID-19 vaccines will be enrolled. new ARD and prevalence of different MSK manifestations after covid-19 vaccinations also will be reported. The prevalence of flare of ARD after covid-19 vaccinations will be dteremined. Also we will compare between different types and doses of covid-19 vaccinations in inducing ARD or flares. Study Design: Cross sectional study Target population: any patient with pre-existing received any vaccination against covid-19 visiting rheumatology outpatient clinic. -any patient develops MSK manifestations after covid-19 vaccination. The disease activity sataus will be measured according to the type of rheumatic disease. For RA , disease activity score28 will be used, in lupus: SLEDAI, in Behcet : BDCAF, in SpA: BASDAI.
Interventions
BIOLOGICALCOVID-19 vaccination
different types of covid-19 vaccinations.
Sponsors
Cairo University
Study design
Observational model
OTHER
Time perspective
CROSS_SECTIONAL
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Inclusion criteria
Age above 18 years Vaccinated against covid-19 (one dose or fully vaccinated)
Exclusion criteria
Receiving other vaccine e.g influenza Less than 18 years old
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| -Prevalence of new ARD after covid-19 vaccinations | 3 moths | any ARD |
| prevalence of flare of ARD after covid-19 vaccinations | 3 months | flare of any manifestations of the disease |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| comparison between different type of covid-19 vaccine in inducing ARD or flare up. | 3 months | any type of flare |
| Prevalence of non-specific MSK symptoms after Covid-19 vaccine. | 3 months | any MSK symptoms |
| Any correlation between the appearance of MSK symptoms and the patient's medications | 3 months | current medications |
| disease activity status in the patients who developed the ARD symptoms before and after the vaccine. | 3 months | activity assessed by disease activity scores |
| Correlation of the MSK to the 1st and 2nd Covid vaccine dose | 3 months | Correlation of the MSK to the 1st and 2nd Covid vaccine dose |
Countries
Egypt
Contacts
Primary ContactMervat Eissa, MD
Outcome results
None listed